FDA Accepts Supplement for Xeomin (incobotulinumtoxinA) by Merz Pharmaceuticals
The FDA has accepted a supplemental application for Xeomin, a botulinum toxin product from Merz Pharmaceuticals.
Company
Pharmaceutical intelligence for Merz Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.